We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. We are searching for downstream targets of Jak2 in Bcr-Abl positive cells. It is known that c-Myc expression is required for the oncogenic effects of BcrAbl, and that over-expression of c-Myc complements the transformation defect of the Bcr-Abl SH2 deletion mutant. Moreover, the Bcr-Abl SH2 deletion mutant and an Abl C-terminal deletion mutant are deficient in activating c-Myc expression. Since the Jak2 binds to the C-terminal domain of Bcr-Abl and optimal Jak2 activation requires the SH2 domain, we tested whether Jak2 was involved in c-Myc protein induction by BcrAbl. We treated the 32Dp210 Bcr-Abl cells with the Jak2 specific tyrosine kinase inhibitor, AG490, and found that this drug, like the Abl tyrosine kinase inhibitor STI-571, inhibited c-Myc protein induction by Bcr-Abl. Treatment of 32Dp210 Bcr-Abl cells with AG490 also inhibited c-MYC RNA expression. It is also known that c-Myc protein is a labile protein that is increased in amounts in response to various growth factors by a mechanism not involving new Myc protein formation. Treatment of 32Dp210 Bcr-Abl cells with both the proteasome inhibitor MG132 and AG490 blocked the reduction of the c-Myc protein observed by AG490 alone. An adaptor protein SH2-Bb is involved in the enhancement of the tyrosine kinase activity of Jak2 following ligand/receptor interaction. In this regard we showed that the Jak2/Bcr-Abl complex contains SH2-Bb. Expression of the SH2-Bb R555E mutant in 32Dp210 Bcr-Abl cells reduced c-Myc expression about 40% compared to a vector control. Interestingly, we found the reduction of the c-Myc protein in several clones of dominant-negative (DN) Jak2 expressing K562 cells correlated very well with the reduction of tumor growth of these cells in nude mice as compared to vector transfected K562 cells. Both STI-571 and AG490 also induced apoptosis in 32Dp210 cells. Of interest, IL-3 containing medium reversed the STI-571 induced apoptosis of 32Dp210 cells but did not reverse the induction of apoptosis by AG490, which strongly supports the specificity of the inhibitory effects of AG490 on the Jak2 tyrosine kinase. In summary, our findings indicate that Jak2 mediates the increase in cMyc expression that is induced by Bcr-Abl. Our results indicate that activated Jak2 not only mediates an increase of c-MYC RNA expression but also interferes with proteasome-dependent degradation of c-Myc protein.
Introduction
Philadelphia chromosome (Ph)-positive chronic myeloid leukemia is a clonal myeloproliferative expansion of transformed primitive hematopoietic progenitor cells. The Ph results from the reciprocal translocation of the ends of chromosome 9 and 22, which generate several forms of the Bcr-Abl fusion protein. The Bcr-Abl oncoproteins possess a constitutively activated Abl tyrosine kinase activity. It is well established that the activated tyrosine kinase is the driving force responsible for causing leukemia. The activated Bcr-Abl tyrosine kinase stimulates multiple signal transduction pathways affecting growth, differentiation and survival of cells (Deininger et al., 2000) . For example, the Bcr-Abl tyrosine kinase directly activates Stat family members, which are normally activated through Janus kinases for the purpose of regulating growth and differentiation of normal hematopoietic cells (Carlesso et al., 1995; Shui et al., 1996; Ilaria and van Etten, 1996; Chai et al., 1997) . The Jak/Stat pathway is known to be activated in hematopoietic cells by other oncogenic tyrosine kinases such as v-Abl and v-Src (Zhang et al., 2000; Chaturvedi et al., 1997; Danial et al., 1998) . In these cases v-Abl and v-Src activate Jak1 which in turn activates the appropriate Stat family member. In contrast, Bcr-Abl activates Jak2 and Stat5 by separate and apparently independent mechanisms (Xie et al., 2001; Wilson-Rawls et al., 1996; Ilaria and van Etten, 1996) . Concerning Jak2 activation, it is known that Jak2 forms a complex with Bcr-Abl (Xie et al., 2001; Miyamoto et al., 2001) and that Jak2 is activated by tyrosine phosphorylation of the critical tyrosine residue 1007 (Xie et al., 2001) . Additional studies indicate that the oncogenic effects of Bcr-Abl require Jak2 (Xie et al., 2001; Miyamoto et al., 2001) .
Although Jak2 and Stat5 are activated separately by Bcr-Abl, the functional significance of these separate activation events is not completely understood. Since Stat5 is the most prominent tyrosine phosphorylated Stat protein in Bcr-Abl positive cells, most efforts have focused on understanding the effects of Stat5 activation. Recently, it was shown that Stat5 like Jak2 is functionally important for Bcr-Abl transformation (Nieborowska-Skorska et al., 1999; de Groot et al., 1999; Horita et al., 2000; Sillaber et al., 2000) .
The downstream target(s) of Jak2 activation by BcrAbl is unknown. It has been shown that the transcription factor c-Myc is required for Bcr-Abl transformation (Sawyers et al., 1992) , but how Bcr-Abl regulates c-Myc is unknown. Several lines of evidence showed that the Bcr-Abl SH2 mutant is unable to induce c-Myc expression (Afar et al., 1994; Skorski et al., 1997) . Interestingly, we found that the Bcr-Abl SH2 deletion mutant is also deficient in its ability to activate Jak2 kinase (Xie et al., 2001) . In addition, deletion of the C-terminus of Abl also reduces c-Myc expression (Okuda et al., 1998) . This fits with our observation that the C-terminus of Abl is required for Jak2 binding (Xie et al., 2001 ). These observations prompted us to examine whether Jak2 is involved in cMyc induction by Bcr-Abl.
In this study, we show that Jak2 is involved in c-Myc induction by inducing c-MYC mRNA and protecting c-Myc protein from 26S proteasome-dependent degradation. These results indicate that c-Myc is a downstream target of activated Jak2 in Bcr-Abl positive cells. Importantly our results confirm that the Jak2 and Stat5 pathways do not appear to be linked in Bcr-Abl positive cells as they are in cytokine-driven effects but instead Jak2 and Stat5 are independently activated by Bcr-Abl.
Results

Bcr-Abl induces c-Myc expression
It has been shown that c-Myc is required for Bcr-Abl and v-Abl oncogenic transformation (Sawyers et al., 1992) . We examined c-Myc expression in 32D and 32Dp210 Bcr-Abl cells. The 32D cell line is a clone of mouse myeloid cells requiring IL-3 for growth and survival. Expression of Bcr-Abl in these cells abrogates the requirement for IL-3. 32D and 32Dp210 Bcr-Abl cells were starved for WEHI medium (a source of IL-3) for 12 h, and the total cell lysates were used for Western blot analysis to measure c-Myc expression. As expected, we found that 32Dp210 Bcr-Abl cells under these conditions expressed a much higher level of c-Myc than 32D vector-transfected cells (Figure 1a ). This result confirms that Bcr-Abl can induce c-Myc expression in the absence of exogenous IL-3. Moreover, addition of conditioned medium from 32Dp210 Bcr-Abl cells did not support cell proliferation and survival of 32D cells in the absence of IL-3 in the medium, suggesting that Bcr-Abl does not induce IL-3 expression in this cell line (not shown).
Efficient induction of c-Myc requires the SH2 domain of Bcr-Abl Afar et al. (1994) developed a complementation strategy to define signal transduction pathways activated by Bcr-Abl tyrosine kinase. They found hyper-expression of c-Myc efficiently restored transformation activity to the Bcr-Abl SH2 mutant but not to either the Grb2 binding site mutant (Y177F) or the autophos-phorylation site mutant of the Abl kinase domain within Bcr-Abl. Skorski et al. (1997) also showed that mouse bone marrow cells infected with Bcr-Abl SH2 mutant expressed lower levels of c-Myc than those infected with wild-type of Bcr-Abl. We compared the c-Myc expression levels in 32Dvector, We found p210DSH2 had 40% less c-Myc expression compared with wild-type 210 and p210DSH3 mutant (Figure 1a, upper panel) . We have shown that BcrAbl activates Jak2 kinase but the SH2 deletion mutant of Bcr-Abl is defective in its ability to activate Jak2 kinase using anti-phosphotyrosine Western blotting (Wilson-Rawls et al., 1996; Xie et al., 2001) . We also determined that the activity of Jak2 kinase as measured by in vitro kinase assays was strongly reduced in p210DSH2 mutant 32D cells compared to wild-type p210 (Figure 1a , lower panel). Taken together, these results establish that the BcrAbl SH2 mutant is defective both in its ability to activate the Jak2 kinase and to induce c-Myc expression.
Induction of c-Myc requires Bcr-Abl tyrosine kinase activity
We next tested whether the induction of c-Myc protein expression by Bcr-Abl is dependent on its tyrosine kinase activity. We treated 32Dp210 Bcr-Abl cells with STI-571, a specific inhibitor of the Bcr-Abl tyrosine kinase, for 1, 2 and 4 h respectively. As expected we found that the inhibition of Bcr-Abl tyrosine kinase by STI-571, as indicated by the decrease in its phosphotyrosine content (Figure 1c) , significantly inhibited the expression of the c-Myc protein (Figure 1b) . Quantitation of c-Myc protein expression by densitometry showed an 80% reduction in the level of the c-Myc protein after 2 h of treatment with STI-571 at 1 mM ( Figure 1b ). This result indicates that the induction of c-Myc expression by Bcr-Abl is dependent on the oncoprotein's tyrosine kinase activity.
Inhibition of Jak2 tyrosine kinase activity blocks c-Myc induction by Bcr-Abl
We have shown that Bcr-Abl DSH2 mutant is defective both in its ability to activate the Jak2 tyrosine kinase and to induce c-Myc expression (Xie et al., 2001 and Figure 1 ). Because c-Myc complements the transformation defect of the SH2 mutant of Bcr-Abl (Afar et al., 1994) , we tested whether the activated Jak2 kinase in Bcr-Abl expressing cells is involved in induction of cMyc protein expression. We treated 32Dp210 Bcr-Abl cells with the Jak2 kinase specific inhibitor, AG490. We first determined the optimal concentration of AG490 necessary to achieve maximal effects on cMyc protein expression. The results showed that 25 mM AG490 achieved about 50% inhibition of c-Myc expression within 4 h post treatment, whilst 100 mM AG490 gave maximal inhibition (not shown). Using 100 mM AG490, we found that induction of c-Myc expression by Bcr-Abl was inhibited by AG490 in a time -dependent manner ( Figure 2a ). We also measured the inhibition of Jak2 kinase activity by AG490 using in vitro kinase assay, and found that the Jak2 kinase harvested from AG490-treated cells was inhibited by 50% relative to untreated cells (Figure 2b ), as measured by densitometry of the Jak2 protein and kinase levels (not shown).
To exclude the possibility that the inhibition of cMyc induction by AG490 is due to the inhibition of Bcr-Abl kinase activity by AG490, we tested Bcr-Abl tyrosine phosphorylation in cells treated with the Jak2 kinase inhibitor. We found that AG490 did not inhibit Bcr-Abl tyrosine phosphorylation (Figure 2c ). Thus, since both the Bcr-Abl and Jak2 tyrosine kinase are required for c-Myc induction and since Bcr-Abl kinase activates the Jak2 kinase, we think the most straightforward conclusion is that Jak2 mediates cMyc induction by Bcr-Abl.
The Stat5 pathway is not inhibited by AG490
The Stat5 pathway is another pathway activated by Bcr-Abl (Nieborowska-Skorska et al., 1999; de Groot et al., 1999; Horita et al., 2000; Sillaber et al., 2000) , but Stat5 activation is independent of Jak2 kinase (Ilaria and Van Etten, 1996; Xie et al., 2001) . We confirmed that the Jak2 tyrosine kinase is not required to activate Stat5 in Bcr-Abl positive cells, as Stat5 tyrosine phosphorylation was also not affected by AG490 treatment (Figure 2d ).
Bcl-X L is a downstream target of Stat5 and is induced by Bcr-Abl through Stat5 (Socolovsky et al., 1999; Horita et al., 2000; Gesbert and Griffin, 2000) . We found that the expression of Bcl-X L was also not affected by AG490 treatment (Figure 2e ). These results indicate that Jak2 is involved in c-Myc induction in Bcr-Abl positive cells by a mechanism not involving Stat5. These results also indicate that Jak2 and Stat5 are two independent pathways activated by Bcr-Abl.
Jak2 activation increases c-MYC mRNA expression
Numerous studies have demonstrated that the growthregulated expression of c-MYC RNA results from increase in c-MYC gene transcription and increase in c-MYC RNA stability (Jones and Cole, 1987; Luscher and Eisenman, 1990) . It has been reported that Jak2 is essential for activation c-MYC transcription by cytokines (Watanabe et al., 1996) . However, c-MYC induction is independent of Stat5 activation (Mui et al., 1996) . It also has been reported that Bcr-Abl can induce c-MYC transcription through transcription factor E2F1 in Bcr-Abl transformed myeloid cells (Stewart et al., 1995) . Since we have shown that BcrAbl can activate Jak2 tyrosine kinase (Wilson-Rawls et al., 1996; Xie et al., 2001) , we tested whether Jak2 is involved in c-MYC RNA expression in Bcr-Abl transformed cells. 32Dp210 cells were treated with the Jak2 inhibitor, AG490, for different times and Northern blot analysis was performed to detect changes in c-MYC RNA expression. We found that AG490 inhibited c-MYC RNA expression in a time-dependent manner ( Figure 3a) . As a control, we also found that the Bcr-Abl kinase inhibitor STI571 also blocked c-MYC RNA expression (Figure 3b ). These results indicate that Jak2 is directly involved in the regulation of c-MYC RNA expression by Bcr-Abl.
Jak2 activation stabilizes c-Myc
We showed that Jak2 is involved in the increase of c-MYC RNA expression that is induced by Bcr-Abl in 32Dp210 cells. However, post-translational control of the c-Myc protein level has also been shown to contribute to the regulation of c-Myc protein. The cMyc protein has an extremely short half-life, which is estimated to be about 20*30 min in growing cells (Hann and Eisenman, 1984; Ramsay et al., 1986) . Its regulated destruction is through the ubiquitin/26S proteasome pathway (Ciechanover et al., 1991; Flinn et al., 1998; Gross-Mesilaty et al., 1998; Salghetti et al., 1999) . Because Bcr-Abl cells have relatively high levels of c-Myc protein, we determined whether or not Bcr-Abl may also regulate the stability of c-Myc protein through activated Jak2. We incubated 32Dp210 Bcr-Abl cells with AG490 for 1, 2 and 4 h with or without MG132 (a 26S proteasome inhibitor), respectively, and found a significant increase in the level of c-Myc protein in 32Dp210 cells in the presence of MG132 (Figure 3c , compare left and right lanes of the top panel). MG132 also partially prevented the reduction of c-Myc protein induced by STI-571 treatment (Figure 3d ). These results indicate that Bcr-Abl through activated Jak2 kinase maintains a high level of c-Myc protein partially through protection of the c-Myc protein from ubiquitin/26S proteasome-dependent degradation.
SH2-Bb R555E mutant decreases expression of c-Myc induced by Bcr-Abl
Our experimental results indicate that the Jak2 tyrosine kinase mediates the up-regulation of c-Myc expression induced by Bcr-Abl since a Jak2 kinase inhibitor, AG-490, strongly inhibited c-Myc expression in the mouse myeloid 32D cell line that expresses P210 Bcr-Abl (Figure 2) . We reasoned that since Jak2 is required for c-Myc up-regulation, then any action that reduces Jak2 kinase activity would also reduce c-Myc up-regulation in 32Dp210 cells. Dr Carter-Su and colleagues have shown that SH2-Bb expression enhances Jak2 kinase activity (Rui and Carter-Su, 1999; Rui et al., 2000) . Therefore, we analysed Jak2/Bcr-Abl complexes from 32Dp210 cells by immunoprecipitation with anti-Jak2 antibody. Immune complexes were analysed by Western blotting with anti-phosphotyrosine antibody (Figure 4a ). Several phosphotyrosine-containing proteins were detected in the Jak2/Bcr-Abl complex from 32Dp210 cells (right lane) that were not observed in 32D vector transfected cells (left lane). The blot was stripped and reprobed with several different antibodies in order to identify the proteins present in the Jak2/ Bcr-Abl complex. The complex from 32Dp210 cells contained P210 Bcr-Abl, Jak2, and the SH2-Bb protein (Figure 4b -d) . Carter-Su and colleagues showed that a SH2-Bb SH2 deletion mutant functions as a dominant negative mutant which inhibits ligand-stimulated activation of Stat5B by endogenous receptor and JAK2 in cells responding to growth hormone (Rui et al., 2000) . We transfected a similar SH2 mutant, SH2-Bb R555E which has a point mutation in the FLVRES motif of SH2 domain and is defective for binding phosphotyrosine, into 32Dp210 cells under puromycin selection to determine the effects of its expression on c-Myc expression in 32Dp210 cells. Compared to vectortransfected cells, expression of the SH2-Bb R555E mutant in 32Dp210 cells resulted in approximately 40% less c-Myc expression (Figure 5a -d) . These findings provide supportive evidence for the critical role of the Jak2 tyrosine kinase activity in the upregulation of c-Myc, which is induced by Bcr-Abl. 
Dominant-negative (DN) Jak2 inhibits c-Myc induction in CML cell line K562
We have several clones of K562 cells that express DN Jak2 (K882E in kinase domain). Compared to vector transfected clones of K562 cells, these clones have reduced tumor-forming ability in nude mice and also have reduced ability to form colonies in soft agar (Xie et al., 2001) . We compared c-Myc induction in several clones of the DN Jak2 K562 cells (Figure 6a) . The results showed that compared to vector-transfected cells, DN Jak2 transfected K562 cells had significantly reduced levels of c-Myc protein expression. Importantly, the reduced tumor-formation abilities of several clones of DN Jak2 K562 cells correlated with the reduction of c-Myc expression in these DN Jak2 cell clones relative to vector controls (Figure 6b ). The reduction in c-Myc expression by DN Jak2 support our findings with both the Jak2 kinase inhibitor AG490 (Figure 2 ) and SH-Bb R555E mutant (Figure 5 ), which indicate a requirement for the Jak2 kinase in the induction of c-Myc protein by the Bcr-Abl oncoprotein.
Treatment of cells with a Jak2 kinase inhibitor causes 32Dp210 cells to undergo apoptosis
To examine whether Jak2 is involved in cell survival of Bcr-Abl positive cells, we again used the Jak2 kinase inhibitor, AG490, to treat 32Dp210 cells. We found that AG490 induced cell death in a dose-dependent manner (achieving 25% apoptosis at 50 mM) as determined by Annexin V/PI staining of 32Dp210 cells (Figure 7a, left panel) . As expected, the Bcr-Abl tyrosine kinase inhibitor, STI-571, also induced apoptosis in 32Dp210 cells (Figure 7b, left panel) . Controls involving the use of identical levels of DMSO, which is used to dissolve AG490, did not induce apoptosis.
To determine whether apoptosis effects induced by AG490 involve the Jak2 tyrosine kinase, we performed a rescue experiment to reverse the apoptotic effects with IL-3. The rationale for this experiment is that since IL-3 is known to activate Jak2 in 32D cells, treating 32Dp210 cells with IL-3 should activate Jak2 even when the Bcr-Abl tyrosine kinase is blocked by STI-571. However, when the Jak2 tyrosine kinase is blocked by AG490, IL-3 treatment should not reverse the induction of apoptosis. This was exactly what was observed in these experiments (Figure 7a ,b, right panels). Thus, these results provide strong evidence that Jak2 has an important role in the cell survival 
Discussion
Our studies have shown that activation of Jak2 by BcrAbl induces increased expression of the c-MYC oncogene, which required the SH2 domain for optimal activation (Figure 1 ). This increased c-Myc expression is inhibited either by treatment of cells with the Abl tyrosine kinase inhibitor STI 571 (Figure 1 ) or by the Jak2 kinase inhibitor AG490 (Figure 2 ). We examined Jak2/Bcr-Abl complexes in 32Dp210 cells and found that phosphotyrosine-containing SH2-Bb was present in the Jak2/Bcr-Abl complex, along with several other phosphotyrosine proteins of unknown identity ( Figure  4 ). SH2-Bb is known to enhance the activity of Jak2 (Rui and Carter-Su, 1999; Rui et al., 2000) . In their studies, a SH2 deletion mutant SH2-Bb was shown to act as dominant negative regulator of Jak2. In our studies, expression of a similar SH2 deficient mutant, SH2-Bb R555E, in 32Dp210 cells reduced the level of c-Myc expression by 40% ( Figure 5) . Furthermore, the reduction of c-Myc protein levels in DN-Jak2 expressing K562 cells correlated very well with the reduction of tumor formation (Figure 6 ). Thus, these results confirm the effects of AG490 treatment on c-Myc protein expression and reinforce the concept that the Jak2 tyrosine kinase mediates the effects of Bcr-Abl regarding increased expression of c-Myc. c-Myc induction by Bcr-Abl via Jak2 also involved induction of c-MYC RNA expression, as AG490 inhibited c-MYC RNA expression (Figure 3a) . Bcr-Abl also inhibited c-Myc protein degradation since an inhibitor of the ubiquitin/26S proteosome pathway, MG132, partially prevented the reduction of c-Myc protein expression induced by AG490 and STI-571 ( Figure  3c,d ). These effects of Jak2 activation were independent of the activation of Stat5 by Bcr-Abl (Figure 2d ). Moreover, AG490 treatment did not affect levels of Bcl-X L (Figure 2e) . Also, the effects of the Jak2 kinase inhibitor, AG490, did not affect the tyrosine kinase activity of Bcr-Abl (Figure 2c) . Importantly, inhibition of Jak2 kinase activity has been shown to induce apoptosis in Bcr-Abl expressing leukemia cells (Miyamoto et al., 2001) . We observed similar results and showed that AG490 induced apoptosis in 32Dp210 cells but that this induction could not be reversed by addition of IL-3 containing WEHI medium (Figure 7a ). In contrast, the wellknown induction of apoptosis by STI-571 was largely reversed by IL-3/WEHI medium (Figure 7b ). The mechanism of apoptosis induction by AG490 is not known but it has been reported that c-Myc is involved in the anti-apoptotic effects of the Tel-PDGFRb oncogenic fusion protein (Besancon et al., 1998) .
Our findings regarding Jak2 involvement with c-Myc expression are consistent with the finding of other groups. For example, the SH2 deletion mutant of BcrAbl has reduced transformation activity, and this reduction involves c-Myc. In our studies, the SH2 deletion mutant has reduced ability to induce tyrosine phosphorylation of Jak2 (Xie et al., 2001) , which would lead to reduced levels of c-Myc (Figure 1) . Importantly, the oncogenic activity of the Bcr-Abl SH2 mutant can be restored by co-expression of c-Myc (Afar et al., 1994) . This complementation of the SH2 defect by c-Myc expression does not restore the oncogenic activity of the Y177F mutant of Bcr-Abl involved in activating the Ras pathway, nor does it complement the mutation within the Abl kinase domain, which is required for Bcr-Abl oncogenic activity. Of interest, the C-terminus of Abl within the Bcr-Abl oncoprotein was shown to be required for the induction of c-MYC transcription (Okuda et al., 1998) . In this regard, we have demonstrated that the Cterminus of Bcr-Abl is required for strong binding to Jak2 (Xie et al., 2001) . The mechanism by which Jak2 Figure 7 Jak2 activation by Bcr-Abl is involved in preventing cell death. (a) 32Dp210 cells were incubated with the Jak2 kinase inhibitor AG490 (50 mM) for 16 h in either standard medium or IL-3 (WEHI)-supplemented medium and apoptosis was assayed by Annexin V-FITC/propidium iodide staining using flow cytometry (about 10 000 cells were assayed in each case). (b) 32Dp210 cells were incubated with the Abl kinase inhibitor STI-571 (2 mM) for 16 h either in standard medium or IL-3 supplemented medium, and apoptosis measured as in (a) c-Myc induction by Bcr-Abl requires Jak2 S Xie et al mediates c-Myc induction is largely unknown. It is known that Bcr-Abl can induce c-MYC transcription through E2F1 binding sites in the c-MYC promoter (Stewart et al., 1995) . It has been reported that STAM is a downstream target of Jak2 and is involved in induction of c-MYC transcription by activated Jak2 (Takeshita et al., 1997) . Two NF-kB binding sites have been identified within the c-MYC promoter/enhancer (La Rosa et al., 1994) . It has been shown that NF-kB is activated by Bcr-Abl (Reuther et al., 1998) . Of interest, it was recently reported that Jak2 is involved in NF-kB activation (Digicaylioglu and Lipton, 2001 ). It will be interesting to know whether STAM and/or NF-kB are involved in induction of c-MYC transcription through Jak2 in Bcr-Abl transformed cells. Akt/ GSK-3b pathway has been shown to be involved in cMyc degradation (Sears et al., 2000) . Importantly, activated Akt protects c-Myc from protein degradation. It is known that Bcr-Abl can activate Akt (Skorski et al., 1997) , but the mechanism by which Bcr-Abl activates Akt is not clearly understood. It has been shown that Jak2 and the common b chain of IL-3/IL-5/GM-CSF receptor are involved in Akt activation induced by these cytokines (Dijkers et al., 1999) . However, we do not know whether Jak2 is also involved in Akt activation induced by Bcr-Abl and whether Akt is involved in protection of c-Myc from degradation in Bcr-Abl transformed cells. We are currently investigating the mechanism involved with c-Myc induction by Bcr-Abl.
These findings suggest a model (Figure 8 ) whereby Bcr-Abl binds to Jak2 through its C-terminus causing Jak2 to be tyrosine-phosphorylated at the site (Y1007) that activates the Jak2 tyrosine kinase. This activation leads to induction of c-MYC mRNA transcription and to an increase in c-Myc protein stability; the latter by blocking c-Myc degradation through a ubiquitin/26S proteosome pathway (as shown in Figure 3) . Therefore, increasing c-MYC RNA expression and protecting c-Myc protein from the ubiquitin/26S proteosome-dependent degradation are involved in maintaining high levels of c-Myc protein in Bcr-Abl positive cells. Surprisingly, Jak2 activation by Bcr-Abl is not directly involved in Stat5 activation, as demonstrated by the data in Figure 2 showing that blocking Jak2 kinase by the AG490 inhibitor did not interfere with Stat5 activation. In addition, previously published results from our laboratory (Xie et al., 2001) and another group (Ilaria and van Etten, 1996) showed that DN-Jak2 did not affect Stat5 activation in Bcr-Abl cell. Instead, Bcr-Abl appears to directly activate Stat5 (Nieborowska-Skorska et al., 1999; de Groot et al., 1999; Horita et al., 2000; Sillaber et al., 2000) . Therefore, Jak2 and Stat 5 are not linked as they are in cytokine induced signaling pathways but are two independent pathways activated by Bcr-Abl. It has been shown that c-Myc is involved in tumor progression through disruption of the Arf-p53 tumor suppressor pathway and therefore induction of genome instability (Sherr, 1998) . Here we show that Jak2 is a major mediator of c-Myc induction by Bcr-Abl, which would also induce genome instability, an event that is crucial for CML progression, but the mechanism of the latter is largely unknown. Thus, our findings raise the possibility that the Jak2/c-Myc pathway may play an important role in CML progression.
Materials and methods
Reagents
MG132 and AG490 were purchased from Calbiochem, San Diego, CA, USA. STI-571 was a gift from Norvartis Pharmaceuticals, East Hanover, NJ, USA. Anti-Myc for Western blotting (sc-764), anti-Myc for the myc tagged SH2-Bb (sc-40), anti-Stat5 (sc-835), anti-Jak2 for immunoprecipitation (sc-294AC), anti-Jak2 for Western blotting (sc-278) and anti-Bcl-X L (sc-7195) antibodies were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Antiphosphotyrosine antibody, 4G10, was purchased from Upstate Biotechnology, Lake Placid, NY, USA. Anti-actin antibody (A5316) was purchased from Sigma, St. Louis, MO, USA. Anti-Abl monoclonal antibody, 8E9, was produced by our own laboratory (Guo et al., 1993) . Anti-SH2-Bb was obtained from Dr Carter-Su (University of Michigan at Ann Arbor). The myc-tagged SH2-Bb R555E plasmid was also provided by Dr Carter-Su.
Tissue culture and transfection 32DpSRatkneo vector, 32DpSRtkaneoP210, 32DpSRat-kneop210DSH2 and 32DpSRatkneop210DSH3 cells were kindly provided by Dr Tomasz Skorski (Temple University, Philadelphia, PA, USA). 32DpSRatkneo vector and 32ppSRatkne0p210DSH2 cells were cultured in DMEM with 10% FCS plus 10% WEHI medium. pSRatkneop210DSH3 cells were cultured in DMEM with 10% fetal calf serum. All cells were maintained in a 7% CO 2 incubator at 378C. The SH2Bb R555E plasmid and pBABE puro were inserted into 32DP210 cells at a 20 : 1 ratio by electroporation. Electroporation was performed at 0.25 V/960 mF using Gene Pulser II System (Bio-Rad, Hercules, CA, USA). Cells were allowed to recover for 48 h in DMEM with 10% FBS without puromycin. After 2 days, puromycin was added to a final concentration of 1 mg/ml in normal growth media. The majority of the cells die rapidly (i.e., 24 -48 h) and a pooled puromycin-resistant cell line was obtained in 10 -14 days. The expression of the SH2Bb R555E mutant was confirmed by Western blotting.
Immunoprecipitation and Western blotting
Cells were lysed in 1% Triton X-100 lysis buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 10% glycerol, 1 mM sodium vanadate, 10 mM sodium fluoride, 10 mM EDTA, 100 KIU/ml protease inhibitor Trasylol (Miles Inc, Kankakee, IL, USA), and 0.1 mg/ml protease inhibitor, 4 (2-aminoethyl) benzenesulfonyl fluoride hydrochloride ( Jak2 kinase assay 32Dp210 cells were treated with 100 mM AG490 for 1, 2 and 4 h, respectively. Cells were lysed in 1% Triton X-100 lysis buffer as above. The concentration was determined by Coomassie 1 plus protein assay reagent and an equal amount of protein was used for immunoprecipitation with the Jak2 antibody, SC-294AC. The beads coupled with Jak2 immune complex were washed twice with lysis buffer, and then once with kinase buffer (10 mM HEPES, pH 7.6, 50 mM NaCl, 0.1 mM Na 3 VO 4 , 5 mM MnCl 2 , 5 mM MgCl 2 ). The beads were resuspended in 30 ml kinase buffer containing 10 mCi of [g-32 P-ATP] (Cat.#35001X; ICN Radiochemicals; Irvine, CA, USA) and incubated at room temperature for 30 min.
Reactions were terminated by adding 1 ml of cold lysis buffer, and beads washed twice with lysis buffer. The proteins were separated on an 8% SDS -PAGE and visualized by phosphoimager (Molecular Dynamics; Sunnyvale, CA, USA).
Northern blotting
Total RNA was extracted with TRIZOL 1 Reagent (Cat. # 15596; Life Technologies; Rockville, MD, USA) from treated cells. Twenty mg of total RNA per each lane was loaded on an agarose/formaldehyde gel. The RNA was transferred to Hybond-N membrane (Amersham Pharmacia Biotech; Buckinghamshire, UK). The c-Myc cDNA probe and human GAPDH cDNA probe were labeled with 50 mCi a-32 P-dCTP (Cat. # BLU513H; NEN TM Life Science Products; Boston, MA, USA) using Random primer labeling Kit (Cat. #1004760; Roche Molecular Biochemicals; Indianapolis, IN, USA). The membrane was pre-hybridized for 3 h and hybridized for 16 h according to Molecular Cloning (Sambrook et al., 1989) . Then, the membrane was washed and visualized with phosphoimager.
Apoptosis assay
Apoptosis of either STI-571 or AG490 treated cells was assayed with an Annexin V staining kit (Cat. #K2025-1, Clontech, Palo Alto, CA, USA). Briefly, treated cells were rinsed with binding buffer once and resuspended in 200 ml of binding buffer, and then 5 ml of Annexin V and 10 ml of propidium iodide were added to the cells. The cells were incubated at room temperature for 15 min in the dark and then analysed by flow cytometry.
